Skip to main content
OpenTrials
Completed

NCT Number: NCT01368341

Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice

Tick borne diseases are increasing in Norway. Lyme borreliosis is the most common infection. Erythema migrans is mainly diagnosed and treated in general practice. There is disagreement about what antibiotic treatment that should be given. An RCT with the three most common antibiotics used, will support data for revision of national guidelines.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Comparison of phenoxymethylpenicillin, doxycycline and amoxicillin for Erythema migrans in Norwegian general practice. Every patient receives 14 days of antibiotic treatment. There are blood samples for measurement of Borrelia antibody level at day 1, 14 and 90 and questionnaires on subjective health complaints (SHC) at day 1, 90 and 360. Side symptoms and side effects are registered. For volunteers there is an additional PCR-analysis on punch biopsy from the EM for subgrouping of the Borrelia bacteria. TBE-antibodies are measured on day 14. Antibody levels and SHC-scores are compared to healthy blood donors.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of Erythema migrans
  • Over the age of 18
  • Signing an concent form after information in writing

Exclusion criteria

  • Allergic to any of the three drugs in the study
  • Under the age of 18
  • Pregnancy
  • Dementia or known drug abuse
  • Antibiotic treatment last 14 days
  • Concommitant Chemotherapy or immunomodulating therapy
  • Concommitant use of medicine with potential interaction (defined in protocol)

Treatment and study plan

Doxycycline

Drug

1 tablet, 100 mg, b.i.d. 14 days

Other names: Doksycycline 100 mg HEXAL, no. 30

Phenoxymethylpenicillin

Drug

Tablet 650 mg, 2 tablets, t.i.d., 14 days

Other names: Weifapenin 650 mg, WEIFA, no. 100

Amoxicillin

Drug

Capsula, 500 mg, t.i.d., 14 days

Other names: Amoxicillin 500 mg MYLAN, no. 30 + 20.

Primary outcomes

  1. Duration of Erythema migrans (EM)

    Time frame: 1-90 days

    On day 1 duration until first the consulation is registered. Day 1-14 the EM is registered in a patient diary. On day 14 the doctor is asked whether the EM has disseapeared. If not the patient is followed by phone from the researchers. On day 90 they are additionally asked for how long it lasted.

Secondary outcomes

  1. Subjective Health Complaints (SHC)

    Time frame: 1 year

    By questionnaire on day 1, day 90 and day 360 the patients are asked about their SHC which is a standardized set of parametres. The 3 treatment groups are compaired to each other and to 1200 healthy blood donors receiving the same questionnaire. There are 29 standardized and 3 Lyme disease related subjects to be measured.

  2. Borrelia antibodies

    Time frame: 1-90 days

    Normally antibody production is not measured for EM as it is a clinical diagnosis, and less than 50 percent of EM-patients are expected to develop antibodies in the first period. However antibodies are here measured on day 1, day 14 and day 90 to see whether there are differences between the groups. Also the results will be compared to the blood donors.

  3. Side symptoms

    Time frame: 1-14 days

    The EM in it self is often asymptomatic, and fever, headache and nerval palsy can be a sign of disseminated disease or co-infection. On the quiestionnaire to the pasient and doctor on day 1, in the patient diary day 1-14 and on the questionnaire to the doctor on day 14 these side symptoms are registered.

    In a potential case, where it turns out that the patient suffers from disseminated disease this will be regostered as treatment failure in the study and the patient treated and/or referred as normal.

  4. Side effects

    Time frame: 1-14 days

    The antibiotic tretments are expected to be non-inferior to each other. Potensial side effects as nausea, diarrhea etc. are registered in the patients diary day 1-14 and in the doctors quiestionnaire on day 14.

  5. Subgrouping and TBE

    Time frame: 1-14 days

    For volunteers there is an additional PCR-analysis on punch biopsy from the EM for subgroupring of the Borrelia bacteria. TBE-antibodies are measured on day 14.

Sponsors and collaborators

Lead sponsor

Morten Lindbaek

Other

Collaborators

  • Norwegian Institute of Public Health
  • Norwegian University of Life Sciences
  • Sorlandet Hospital HF

Registry information

Official study title

Tick Borne Diseases in Norwegian General Practice. A Randomized, Controlled Trial for Treatment of Erythema Migrans in Norwegian General Practice. A Comparison of Phenoxymethylpenicillin, Amoxicillin and Doxycycline.

Acronym: NorTick_EM

Important dates

Study start
2011
Primary completion
2013
Study completion
2014
First posted
Jun 7, 2011
Registry last updated
Dec 12, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.